Publications in: “26/07/2019”

Use of Ribaxamase (SYN-004), a beta lactamase, to prevent Clostridium difficile infection in Beta lactam treated patients: a double blind phase randomized placebo controlled trial

Beta lactam antibiotics are considered risk factors for clostridioides difficile infection. These antibiotics are excreted by the bile in the gut and maintain antibiotic levels at this site. Ceftriaxone is highly excreted by the biliary tree. This excretion can continues up to 48 hours after discontinuation of intravenous ceftriaxone and may lead to concentrations as high as 1 mg/ml in the intestinal fluid. Ribaxamase degrades beta lactams and could help preventing C diff infection. This was a study including 433 […]